“Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s291. doi:10.25251/skin.7.supp.291.